Abstracts tagged "prolactin and systemic lupus erythematosus (SLE)"

Abstract Number: 759 • 2015 ACR/ARHP Annual Meeting
Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients
Manuel Ugarte-Gil^1,2, César Sánchez-Zúñiga³, Rocio V. Gamboa-Cardenas¹, Madeley Aliaga-Zamudio³, Francisco Zevallos¹, Giannina Tineo-Pozo³, Jorge M. Cucho-Venegas¹, Ana Mosqueira-Riveros³, Risto Perich-Campos^1,4, Jose Alfaro-Lozano¹, Mariela Medina¹, Zoila Rodriguez-Bellido^1,4, Graciela S. Alarcon⁵ and Cesar A. Pastor-Asurza^1,4, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Molecular Biology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Peripheral CD4+CD28null T-cells are a subset of long-lived cytotoxic CD4+ T-cells with pro-inflammatory functions, and they are increased in autoimmune and cardiovascular diseases. Prolactin…
Abstract Number: 1625 • 2013 ACR/ARHP Annual Meeting
Prolactin-Induced Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation In Monomac-6 Cells Correlating With Changes Seen In Monocytes From Systemic Lupus Erythematosus Patients
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Michelle Petri³ and Kate Sullivan⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease and missing heritability. Therapies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].